Cogent Biosciences Inc (COGT) concluded trading on Thursday at a closing price of $12.2, with 3.68 million shares of worth about $44.86 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 65.54% during that period and on July 17, 2025 the price saw a gain of about 2.87%. Currently the company’s common shares owned by public are about 163.81M shares, out of which, 126.05M shares are available for trading.
Stock saw a price change of 12.44% in past 5 days and over the past one month there was a price change of 62.88%. Year-to-date (YTD), COGT shares are showing a performance of 31.89% which increased to 56.41% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.72 but also hit the highest price of $12.61 during that period. The average intraday trading volume for Cogent Biosciences Inc shares is 2.65 million. The stock is currently trading 37.18% above its 20-day simple moving average (SMA20), while that difference is up 75.14% for SMA50 and it goes to 53.08% higher than SMA200.
Cogent Biosciences Inc (NASDAQ: COGT) currently have 163.81M outstanding shares and institutions hold larger chunk of about 71.09% of that.
The stock has a current market capitalization of $2.00B and its 3Y-monthly beta is at 0.30. It has posted earnings per share of -$2.38 in the same period. It has Quick Ratio of 5.13 while making debt-to-equity ratio of 0.08. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for COGT, volatility over the week remained 5.62% while standing at 7.34% over the month.
Stock’s fiscal year EPS is expected to rise by 10.62% while it is estimated to increase by 11.17% in next year. EPS is likely to grow at an annualized rate of 29.08% for next 5-years, compared to annual growth of 10.02% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Scotiabank on March 07, 2025 offering a Sector outperform rating for the stock and assigned a target price of $17 to it. On February 26, 2024, Robert W. Baird Downgrade their recommendations, while on February 08, 2024, Citigroup Initiated their ratings for the stock with a price target of $11. Stock get a Neutral rating from Wedbush on December 11, 2023.
